TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Orthotopic Liver Transplantation Using a Living Donor

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-55~2. No current or prior history of heart, lung or other medical problems.~3. No history of liver disease.~4. No history of malignancy, except limited basal cell carcinoma.~5. ABO / HLA compatibility with the recipient.~6. If female and premenopausal, a negative pregnancy test.~7. Related to recipient either by blood or marriage and having a stable, long term, emotional relationship.~8. The donor's body size and volumetric determination of liver mass by abdominal CT scan will indicate whether or not a donor is a suitable candidate for liver donation if the donor meets the other inclusion criteria. Favorable donors for the individual organs will be those with donor graft to recipient body dry weight ratios (GRBWR) of \>0.7% and those with a ratio of graft volume to recipient's expected liver volume (GWRLW) of \>35%.~9. Satisfactory psychosocial evaluation. -~Exclusion Criteria:~Recipient Exclusion Criteria:~1. Pregnant or nursing females.~2. Patients with significant concomitant infections.~3. Patients who require multiple organ transplants.~4. Significant pulmonary disease. If pulmonary disease is clinically suspected, diagnostic studies will be performed to exclude the presence of pulmonary hypertension (PA systolic pressure \>40 mm Hg) or arterial saturation (Po2\<60 mmHg, breathing room air).~5. Patients at a higher than average perioperative risk secondary to severe decompensated liver disease or previous surgery (i.e., re-transplantation) or infections.~   -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Routine Pregnancy Screening for Women on Opioid Substitution Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* currently on methadone or buprenorphine maintenance therapy~* have some male sexual partners~Exclusion Criteria:~* females who have exclusively female sexual partners~* a previous diagnosis of premature menopause~* hysterectomy, oophorectomy, and/or tubal ligation~* current pregnancy~* current intrauterine device (hormonal or non-hormonal)~* unable to give informed consent in English

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Monthly Pregnancy Screening (Type: EXPERIMENTAL): Patients at the Hamilton Clinic present to the clinic most often on a weekly basis to provide a urine sample for urine drug screening and to meet with their MRP. This same urine sample will be tested for pregnancy in the intervention group once per month. Resulting positive test results will be reported to the patient through their attending physician on the day of testing.
- Usual Care (Type: ACTIVE_COMPARATOR): Participants in the control group will not receive study-initiated urine pregnancy testing but will receive usual care, which may include pregnancy testing based on patient request or clinical judgement.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Paracervical Injection for Headache in the Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 64 years~* Suspected diagnosis of benign or primary headache~Exclusion Criteria:~* Treating attending physician is suspicious of a serious secondary cause of headache~* History of brain disease, concussion, stroke, intracranial mass or tumor, hemorrhage, increased intracranial pressure, head trauma in last 2 weeks, status post intracranial surgery~* History of neck disease, cervical spine or disc abnormality, history of vertebral or carotid artery dissection, torticollis, status post cervical spine surgery or hardware in place~* Hypersensitivity or allergy to bupivacaine (amide anesthetics) or prochlorperazine (dopamine receptor antagonists)~* Overlying signs of infection at site of injection (erythema, purulence, open skin)~* History of extrapyramidal symptoms, dystonia, parkinsonism, tardive dyskinesia or neuroleptic malignant syndrome~* Pregnancy~* History of schizophrenia or bipolar disorder~* Narcotic seeking patients as determined by the treating attending physician with optional assistance from medical record and online database review~* Weight more than 150 kg or less than 40 kg~* Received pain medication in the ED or less than 6 hours prior to enrollment~* Temperature greater than 38 degrees Celcius~* Previous enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Paracervical injection (Type: EXPERIMENTAL): 1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine.
- Standard treatment (Type: ACTIVE_COMPARATOR): Intravenous administration of prochlorperazine and diphenhydramine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Psychosocial Development of Maltreated Children: A Prospective Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Inpatients~* Outpatients~* Sexual abuse~* Physical maltreatment~* Psychological maltreatment~* Neglect~* Substantiated maltreatment~* Indicated maltreatment~* Aged 0-15 years at recruitment~Exclusion Criteria:~* telephone counseling~* Munchausen Syndrome by proxy~* Maltreatment not confirmed~* Aged 16 years and older at recruitment

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 15 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Progesterone in Pregnancy-2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18yo~* Singleton gestation, ≥36 0/7 weeks gestation~* Scheduled cesarean delivery at Thomas Jefferson University Hospital or affiliate~Exclusion Criteria:~* Contraindication to vaginal progesterone suppository~  * Active hepatic disease~ * Prior or current thrombus~ * Known adverse reaction to progesterone~ * Peanut allergy~* Bleeding disorder (such as thrombophilia)~* Use of 17-hydroxyprogesterone caproate in the pregnancy~* Use of vaginal progesterone in the pregnancy~* History of adverse reaction to progesterone~* Current vaginitis

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Vaginal progesterone (Type: ACTIVE_COMPARATOR): 200mg micronized vaginal progesterone placed 7am prior to scheduled cesarean delivery
- Control (Type: NO_INTERVENTION): No intervention, scheduled cesarean delivery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Genetic Epidemiology and Energy Metabolism in Black Girls

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
No eligibility criteria

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Ex Vivo Stimulation of Whole Blood as a Means to Determine Glucocorticoid Sensitivity to Mild-to-Moderate and Refractory Asthmatics

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~To be eligible for the study, subjects must meet all of the following criteria:~* Age ≥ 18 years old~* Physician diagnosis of asthma confirmed through medical record documentation.~* Documented history of 12% FEV1 reversibility post-bronchodilator and/or Methacholine PC 20 score of 16mg/ml or less.~* Non-smoker for \> 6 months before enrollment into the trial~* Less than 5 pack year smoking history defined as the average packs smoked per day multiplied by the years of active smoking.~* Willing and able to adhere to the study visit schedule and other protocol-specified procedures.~Exclusion criteria:~Subjects meeting any of the following criteria may not be enrolled in the study:~* Existence of lung disease (other than asthma)~* Recent asthma exacerbation requiring hospital admissions, unexpected healthcare visits, or prednisone courses in the previous 4 weeks.~* Non-English speaking.~* Participation in another interventional research trial~* Self-reported pregnancy~* Inability or unwillingness to provide consent~* Febrile illness (\>38.0˚ C or 100.4˚ F) within 24 hours of visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy in Treating Patients With Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed Ewing's family tumor as characterized by the following:~  * Positive MIC2 on immunohistochemistry OR~ * Evidence of a chromosomal translocation involving the EWS gene by conventional cytogenetics~    * t(11; 22) translocation or variant OR~   * Demonstration of EWS/FLI1 or EWS/ERG gene fusion by PCR or FISH~* Metastases outside the lung or pleura~* At least 1 measurable lesion outside of previously irradiated area~* No symptomatic or known CNS metastases~PATIENT CHARACTERISTICS:~Age:~* 15 to 65~Performance status:~* WHO 0-2~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 3,000/mm3~* Neutrophil count at least 2,000/mm3~* Platelet count at least 100,000/mm3~Hepatic:~* Bilirubin less than 3 mg/dL~* Albumin greater than 2.5 g/dL~Renal:~* Creatinine less than 1.2 mg/dL~* Creatinine clearance greater than 70 mL/min~Cardiovascular:~* No history of uncontrolled cardiovascular disease~Other:~* No other severe medical illness, including psychosis~* No other prior primary malignancy except adequately treated carcinoma in situ of the cervix or basal cell skin cancer~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* See Disease Characteristics~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Ribose on B-Type Natriuretic Peptide (BNP) Levels in Congestive Heart Failure Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic adults, M/F, between 18 and 80 years of age~* BNP levels equal to or greater than 300 pg/ml.~* Primary or secondary diagnosis of congestive heart failure at the time of admission (any NYHA Class)~* Diagnosis of congestive heart failure for at least 3 months~* Able to perform 6 minute hall walk~* No therapeutic pharmaceutical class changes for at least 1 month~* Provide informed consent~* A 30-day washout period must be achieved for any patient involved in a previous clinical study.~Exclusion~* Insulin dependent diabetes (Type I)~* History of obstructive valvular disease~* History of pulmonary hypertension within the last 3 months~* History of hypertrophic or alcoholic cardiomyopathy~* History of restrictive cardiomyopathy~* History of reversible cardiomyopathy~* History of non-compliance~* Pregnancy~* Current enrollment in any other clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed low-grade astrocytoma that has progressed, recurred, or persisted after initial therapy, including radiotherapy~* Previously treated with at least 1 prior standard therapy (e.g., radiotherapy, chemotherapy, immunotherapy, or cytodifferentiating agent)~* Measurable tumor by MRI scan performed within two weeks prior to study entry~* Tumor must be at least 5 mm~* No brain stem tumors~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* More than 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~* SGOT and SGPT no greater than 5 times upper limit of normal~* No hepatic failure~Renal:~* Creatinine no greater than 2.5 mg/dL~* No renal insufficiency~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No uncontrolled hypertension~* No chronic heart failure~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No severe lung disease (e.g., chronic obstructive pulmonary disease)~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No other concurrent serious disease~* No active infection~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Disease Characteristics~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulating agents~Chemotherapy:~* See Disease Characteristics~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* No concurrent antineoplastic agents~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* See Disease Characteristics~* At least 8 weeks since prior radiotherapy and recovered~Surgery:~* Must recover from prior surgery~Other:~* No prior antineoplastons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cohort Study of Respiratory Illness in Early Childhood

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
No eligibility criteria

- Gender: MALE
- Minimum Age: 0 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven relapsed or refractory low-grade or follicular CD+ non-Hodgkin lymphoma, including 1 of the following:~  * Small lymphocytic lymphoma~ * Lymphoplasmacytoid lymphoma~ * Follicular center lymphoma (grades I, II, and III)~ * Extranodal marginal zone B-cell lymphoma~ * Nodal marginal zone B-cell lymphoma~ * Splenic marginal zone B-cell lymphoma (monocytoid B-cell lymphoma)~* Less than 25% bone marrow involvement of cellular marrow with lymphoma by bilateral bone marrow aspirate and biopsy~* ECOG performance status 0-2~* Bidimensionally measurable disease with at least 1 lesion \>= 2 cm in the greatest diameter~* No prior myeloablative therapy with autologous or allogeneic bone marrow transplantation or peripheral blood stem cell support~* No concurrent corticosteroid therapy, except prednisone (or equivalent) for adrenal failure or \< 20mg of prednisone daily~* No prior external beam radiotherapy to \>25% of active bone marrow~* More than 4 weeks since prior surgery other than diagnostic surgery~* No other concurrent myelosuppressive antineoplastic agents~* No prior radioimmunotherapy, including yttrium Y 90 ibritumomab tiuxetan or iodine I 131 monoclonal antibody tositumomab or Lym-1~* No CNS lymphoma~* No myelodysplastic syndromes or marrow chromosomal changes suggesting myelodysplasia~* No HIV or AIDS-related lymphoma~* No pleural effusion or ascites with lymphoma cells~* No active infection~* No other serious non-malignant disease that would preclude study participation~* No other active primary malignancy~* No known human anti-mouse or human anti-chimeric antibody~* No prior skin rash (e.g., Stevens-Johnsons syndrome or toxic epidermal necrolysis) from rituximab therapy~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Absolute neutrophil count \>= 1,500/mm\^3~* Platelet count \>= 150,000/mm\^3~* Total lymphocyte count \< 5,000/mm\^3 for patients with small lymphocytic lymphoma~* Bilirubin =\< 2 mg/dL~* Creatinine =\< 2 mg/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (radiolabeled monoclonal antibody therapy) (Type: EXPERIMENTAL): Patients receive rituximab IV on days 1 and 8, indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1, and yttrium Y 90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) and interleukin-11 SC until blood counts recover.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Hemodynamic Effects of Stored Blood Transfusion in Intensive Care Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient has a pulmonary artery catheter in place~2. Transfusion of 1 unit of packed red blood cells indicated for standard intensive care therapy~3. The patient has an arterial catheter~Exclusion Criteria:~1. Age \< 18 years~2. Clinical prediction that the patient will not survive at least 48 hours~3. Acute bleeding: \> 2 units of packed red blood cells/hour~4. Vasopressor use: noradrenalin \> 0.2 μg/kg/min or any use of adrenalin within 6 hours of inclusion into the study~5. Therapy with inhaled NO, inhaled prostacyclin, or phosphodiesterase-5-inhibitors~6. Sepsis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fresh blood transfusion (Type: ACTIVE_COMPARATOR): One unit of blood stored for less than 14 days
- Standard issue blood transfusion (Type: EXPERIMENTAL): One unit of blood stored under standard conditions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject~2. Patients with advanced or metastatic renal cell carcinoma, including all subtypes~3. Age ≥ 18 years~4. Completion of treatment with nivolumab or nivolumab / ipilimumab combination therapy (any line of therapy) directly followed by cabozantinib treatment~Exclusion Criteria:~1. Patients who are unable to consent because they do not understand the nature, significance and implications of the observational trial~2. Involvement in the planning and / or conduct of the study (applies to both Ipsen staff and/or staff of sponsor and study site)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues